Published in Lab Law Weekly, August 24th, 2007
"The second quarter was noteworthy for Cyclacel as we continued to make progress in our clinical development programs," said Spiro Rombotis, President and CEO of Cyclacel. "In this quarter we announced encouraging Phase I interim results for oral sapacitabine in patients with advanced leukemias or myelodysplastic syndromes and commenced a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.